COLLABORATIONS AND DEVELOPMENT FUND An essential part of the HARC Center will be to enlist a wide range of collaborators to help further identify and validate HIV-host protein complexes, facilitate structure determination of the complexes, utilize structural information to more deeply probe the biological functions of the HIV regulatory and accessory proteins, and extend technological developments in high-throughput expression, structure determination, MS methods, cryo-EM, and tomography. We will facilitate these essential collaborations by: actively reaching out to relevant researchers through direct contacts; organizing visits of collaborators and possible collaborators to the HARC Center to plan future research directions; providing seed funding for promising collaborations; facilitating funding opportunities for collaborators, including the related R21/R33 mechanism announced by NIAID; widely disseminating the goals, results, and available resources of the HARC Center to encourage further outside participation; and actively participating in national and international meetings. We have requested 5% of the direct cost budget for a Collaboration Development Fund to support these activities. Given the breadth of projects encompassed in the initial establishment of the HARC Center, we have solicited letters from potential collaborators working directly on the accessory and regulatory proteins and technologies that comprise the focus of this project. As the HARC Center becomes more established, new research directions will be evaluated thoroughly by the HARC Center Executive Council and internal and external advisory committees, and directions altered and funds allocated as appropriate. Our initial collaborative efforts are described in more detail in Section IV.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Specialized Center (P50)
Project #
5P50GM082250-02
Application #
7671444
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
2
Fiscal Year
2008
Total Cost
$182,145
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Palovcak, Eugene; Wang, Feng; Zheng, Shawn Q et al. (2018) A simple and robust procedure for preparing graphene-oxide cryo-EM grids. J Struct Biol 204:80-84
Tambe, Akshay; East-Seletsky, Alexandra; Knott, Gavin J et al. (2018) RNA Binding and HEPN-Nuclease Activation Are Decoupled in CRISPR-Cas13a. Cell Rep 24:1025-1036
Paulo, Esther; Wu, Dongmei; Wang, Yangmeng et al. (2018) Sympathetic inputs regulate adaptive thermogenesis in brown adipose tissue through cAMP-Salt inducible kinase axis. Sci Rep 8:11001
Faust, Tyler B; Li, Yang; Bacon, Curtis W et al. (2018) The HIV-1 Tat protein recruits a ubiquitin ligase to reorganize the 7SK snRNP for transcriptional activation. Elife 7:
Eckhardt, Manon; Zhang, Wei; Gross, Andrew M et al. (2018) Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network. Cancer Discov 8:1474-1489
Masand, Ruchi; Paulo, Esther; Wu, Dongmei et al. (2018) Proteome Imbalance of Mitochondrial Electron Transport Chain in Brown Adipocytes Leads to Metabolic Benefits. Cell Metab 27:616-629.e4
Binning, Jennifer M; Smith, Amber M; Hultquist, Judd F et al. (2018) Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors. PLoS Pathog 14:e1006830
Morris, Kyle L; Buffalo, Cosmo Z; Stürzel, Christina M et al. (2018) HIV-1 Nefs Are Cargo-Sensitive AP-1 Trimerization Switches in Tetherin Downregulation. Cell 174:659-671.e14
Chen, Si-Han; Jang, Gwendolyn M; Hüttenhain, Ruth et al. (2018) CRL4AMBRA1 targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling. EMBO J 37:
Leoz, Marie; Kukanja, Petra; Luo, Zeping et al. (2018) HEXIM1-Tat chimera inhibits HIV-1 replication. PLoS Pathog 14:e1007402

Showing the most recent 10 out of 199 publications